Sandoz Partner Gan & Lee Wraps Phase III Insulin Glargine Trial
Follows Earlier Positive Phase I Clinal Data For Biosimilar Rival To Lantus
Sandoz’ partnership with China’s Gan & Lee covering three biosimilar insulin products continues to make progress, with the conclusion of a pair of Phase III trials involving a proposed biosimilar to Lantus (insulin glargine).
You may also be interested in...
Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.
Eli Lilly has been granted an interchangeability designation by the US FDA for its Rezvoglar insulin glargine biosimilar, matching the designation previously granted for Viatris’ Semglee.
With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.